Prostanoid therapy for pulmonary arterial hypertension

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Medical Therapeutics

Background:

• Epoprostenol, discovered in 1976, significantly changed pulmonary arterial hypertension (PAH) therapy.
• Prostanoids, a class of drugs including epoprostenol, treprostinil, iloprost, and beraprost, are crucial in PAH management.
• The therapeutic landscape for PAH has evolved with the development of various prostanoids and agents targeting alternative pathways.

Purpose of the Study:

• To review the impact of prostanoids on PAH treatment.
• To highlight the development of prostanoids with diverse administration routes.
• To discuss emerging research in prostanoid combination therapies and their application in non-PAH pulmonary hypertensive disorders.

Main Methods:

• Literature review of prostanoid discovery and therapeutic applications.
• Analysis of clinical advancements in PAH treatment strategies.
• Examination of ongoing research in pulmonary hypertension management.

Main Results:

• The introduction of epoprostenol marked a turning point in PAH therapy.
• Multiple prostanoid formulations are now available, offering various routes of administration.
• Research continues to expand therapeutic options for PAH and related conditions.

Conclusions:

• Prostanoids represent a cornerstone therapy for pulmonary arterial hypertension.
• The development of novel prostanoids and combination therapies is expanding treatment possibilities.
• Further research is investigating the broader application of prostanoids in pulmonary hypertensive disorders.